MedTrace Logo

Flecainide-Short Long Study (Flec-SL)

NCT00215774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 760

Last updated 2012-09-11

No results posted yet for this study

Summary

A randomized trial to test the hypothesis that short-term pharmacological reversal of electrical remodeling after cardioversion is equally efficient to prevent recurrent atrial fibrillation as standard long-term antiarrhythmic therapy.

Conditions

Interventions

DRUG

Flecainide

Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Meda Pharmaceuticals

    collaborator INDUSTRY

  • German Research Foundation

    collaborator OTHER

  • Atrial Fibrillation Network

    lead OTHER

Principal Investigators

  • P Kirchhof, Prof · AFNET, Kompetenznetz Vorhofflimmern

  • G Breithardt, Prof · AFNET, Kompetenznetz Vorhofflimmern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2009-10-31
Completion
2011-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215774 on ClinicalTrials.gov